Gland Pharma Limited

BSE: GLAND543245ISIN INE068V01023

Healthcare
Pharmaceuticals
BSE 500

Share price

₹3,157.70-2.55 (-0.08%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹3,174.65
52W low: ₹1,575.00
Off 52W high: -0.53%
1M return: +8.40%
3M return: +24.04%
6M return: +74.21%
1Y return: +65.09%
20D avg volume: 92,055
50 DMA: ₹2,959.38
200 DMA: ₹2,294.79

Key ratios Consolidated

Market cap: ₹52,105 Cr
Current price: ₹3,157.70
52W high / low: ₹3,174.65 / ₹1,575.00
Face value: ₹1.00
P/E: 46.16
P/B: 5.02
EPS (TTM): ₹68.41
Book value / share: ₹628.67
ROE: —
ROCE: 13.70%
Operating margin: —
Net margin: —
Debt / equity: 0.02
Net debt: ₹-3,116 Cr
Interest cover: 45.01
Dividend yield: 0.63%
Dividend / share (TTM): ₹20.00
Payout: 29.24%
Cash conversion cycle: 159.1 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	1,800	1,743	1,695	1,487	1,506	1,425	1,384	1,406	1,402	1,537	1,545	1,373
	61.23	111.47	63.17	84.16	57.53	44.03	58.49	59.66	51.43	42.15	37.39	53.16
	1,862	1,854	1,759	1,571	1,563	1,469	1,443	1,465	1,453	1,580	1,583	1,427
	1,427	1,348	1,372	1,287	1,250	1,181	1,143	1,209	1,235	1,281	1,299	1,137
	588.20	594.07	529.89	558.43	557.36	587.57	437.38	485.88	461.65	574.69	464.00	517.92
	1.95	2.28	1.50	1.94	0.88	3.10	2.15	2.66	6.58	6.76	6.38	6.13
	444.00	411.57	424.20	385.03	408.04	373.37	342.86	329.81	355.53	351.61	345.33	304.95
	4.36	10.03	3.93	7.82	11.50	7.45	22.82	6.11	5.62	9.96	5.28	6.05
	111.26	108.66	107.64	106.31	101.05	95.76	96.33	93.83	91.96	92.61	105.34	81.30
	242.58	226.87	259.64	234.15	208.69	216.07	163.87	158.13	171.01	169.93	180.16	164.55
	434.98	505.80	386.47	283.92	312.74	288.33	299.30	256.78	218.25	298.23	283.16	289.89
	0.00	0.00	-24.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	434.98	505.80	362.13	283.92	312.74	288.33	299.30	256.78	218.25	298.23	283.16	289.89
	118.02	139.12	100.65	100.23	97.26	101.79	94.61	93.25	74.48	105.81	91.30	95.81
	316.96	366.68	261.48	183.68	215.48	186.54	204.69	163.53	143.76	192.42	191.86	194.08
	19.23	22.26	15.87	11.15	13.08	11.32	12.42	9.93	8.73	11.68	11.65	11.78
Key metrics
	550.60	624.49	473.70	398.05	425.29	391.54	418.45	356.72	315.83	400.80	393.78	377.24
	30.60%	35.80%	27.90%	26.80%	28.20%	27.50%	30.20%	25.40%	22.50%	26.10%	25.50%	27.50%
	17.60%	21.00%	15.40%	12.40%	14.30%	13.10%	14.80%	11.60%	10.30%	12.50%	12.40%	14.10%
	—	4.70%	—	2.90%	—	3.10%	—	—	—	—	—	—
	19.60%	22.30%	22.50%	5.80%	7.40%	-7.30%	-10.40%	2.40%	—	—	—	—
	47.10%	96.60%	27.70%	12.30%	49.90%	-3.10%	6.70%	-15.70%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21
Income statement
	6,725	6,431	5,616	5,665	3,625	4,401	3,463
	320.03	316.33	213.61	170.24	240.46	223.94	134.78
	7,045	6,747	5,830	5,835	3,865	4,625	3,598
	5,434	5,258	4,767	4,702	2,754	3,006	2,263
	2,271	2,240	1,972	2,022	1,717	2,047	1,749
	7.67	6.60	14.49	23.07	15.59	25.66	16.20
	1,665	1,629	1,402	1,257	403.26	338.57	311.36
	26.14	33.28	42.00	26.20	7.45	5.24	3.41
	433.87	423.67	377.87	344.57	146.74	110.30	98.78
	963.24	929.34	855.64	671.68	386.31	347.72	282.83
	1,611	1,489	1,063	1,133	1,111	1,619	1,335
	-24.35	-24.35	0.00	0.00	-56.46	0.00	0.00
	1,587	1,465	1,063	1,133	1,055	1,619	1,335
	458.02	437.26	364.13	360.08	273.54	406.89	337.85
	1,129	1,027	698.53	772.46	781.04	1,212	996.96
	68.51	62.35	42.40	46.90	47.44	73.81	63.07
Key metrics
	2,047	1,922	1,483	1,503	1,209	1,734	1,437
	30.43%	29.90%	26.40%	26.50%	33.30%	39.40%	41.50%
	16.78%	16.00%	12.40%	13.60%	21.50%	27.50%	28.80%
	—	13.70%	11.40%	—	—	—	—
	17.57%	14.50%	-0.90%	56.30%	-17.60%	27.10%	—
	46.55%	47.10%	-9.60%	-1.10%	-35.50%	21.50%	—
	—	540.63	530.19	—	—	—	—
	—	1.00	1.31	—	—	—	—
	—	0.02	0.03	—	—	—	—
	—	-3,116	-2,287	—	—	—	—
	—	159.1	154.8	—	—	—	—
Balance sheet
	—	12,511	11,225	—	—	—	—
	—	7,527	6,783	—	—	—	—
	—	3,359	2,556	—	—	—	—
	—	1,891	1,517	—	—	—	—
	—	1,744	1,685	—	—	—	—
	—	458.67	531.36	—	—	—	—
	—	4,052	3,751	—	—	—	—
	—	833.87	820.41	—	—	—	—
	—	1,608	1,565	—	—	—	—
	—	243.36	269.21	—	—	—	—
	—	173.44	191.55	—	—	—	—
	—	69.92	77.66	—	—	—	—
	—	10,358	9,151	—	—	—	—
Cash flow
	—	1,031	914.73	—	—	—	—
	—	137.73	1,705	—	—	—	—
	—	-416.97	-433.48	—	—	—	—
	—	490.76	384.54	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	1,287	1,262	1,178	1,074	1,039	1,030	1,011	1,063	1,012	1,175	1,098	1,011
	58.82	106.36	60.21	82.59	54.74	43.72	65.06	57.80	48.49	46.95	43.39	41.11
	1,345	1,368	1,238	1,157	1,094	1,074	1,076	1,121	1,061	1,222	1,141	1,052
	857.77	803.15	800.92	748.07	731.19	682.75	681.72	740.98	760.20	789.10	769.50	704.72
	469.45	460.96	434.85	459.59	439.82	469.39	348.91	399.87	367.69	482.88	378.43	456.62
	1.95	2.28	1.50	1.94	0.88	3.10	2.15	2.67	6.58	6.83	6.38	6.13
	143.91	133.96	134.14	132.28	128.44	119.69	105.36	106.29	107.68	107.87	99.29	99.88
	0.69	6.17	0.50	3.97	7.43	3.45	18.31	0.17	0.91	4.53	0.80	0.91
	43.95	43.11	44.53	44.84	43.77	43.07	43.77	41.62	40.82	42.56	40.33	40.24
	161.97	135.13	157.46	147.38	125.07	111.32	105.43	92.55	102.86	88.55	111.95	93.16
	487.69	564.80	436.80	408.67	362.38	391.32	394.13	379.82	300.31	432.69	371.75	347.06
	0.00	0.00	-24.35	0.00	0.00	0.00	—	—	—	—	—	—
	487.69	564.80	412.46	408.67	362.38	391.32	394.13	379.82	300.31	432.69	371.75	347.06
	123.30	144.35	104.61	106.68	93.12	101.32	99.01	98.11	77.39	111.28	94.95	89.54
	364.39	420.45	307.85	302.00	269.26	290.00	295.12	281.71	222.92	321.41	276.81	257.53
	22.11	25.52	18.68	18.33	16.34	17.60	17.91	17.10	13.53	19.51	16.81	15.64
Key metrics
	532.33	614.08	457.49	457.48	413.58	437.84	456.21	421.61	342.04	479.78	412.88	388.21
	41.40%	48.70%	38.90%	42.60%	39.80%	42.50%	45.10%	39.70%	33.80%	40.80%	37.60%	38.40%
	28.30%	33.30%	26.10%	28.10%	25.90%	28.10%	29.20%	26.50%	22.00%	27.40%	25.20%	25.50%
	—	5.20%	—	4.00%	—	4.00%	—	—	—	—	—	—
	23.90%	22.40%	16.50%	1.00%	2.70%	-12.30%	-7.90%	5.20%	—	—	—	—
	35.30%	45.00%	4.30%	7.20%	20.80%	-9.80%	6.60%	9.40%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21
Income statement
	4,800	4,552	4,116	4,167	3,617	4,401	3,463
	307.98	303.90	215.07	166.67	240.46	223.94	134.78
	5,108	4,856	4,331	4,334	3,857	4,625	3,598
	3,210	3,083	2,866	2,929	2,752	3,006	2,263
	1,825	1,795	1,586	1,710	1,717	2,047	1,749
	7.67	6.60	14.49	23.14	15.59	25.66	16.20
	544.29	528.82	439.02	409.94	399.70	338.57	311.36
	11.33	18.07	22.84	7.84	7.41	5.24	3.41
	176.43	176.24	169.27	162.11	146.74	110.30	98.78
	601.94	565.04	503.91	411.20	388.01	347.23	282.79
	1,898	1,773	1,466	1,406	1,105	1,619	1,335
	-24.35	-24.35	0.00	—	-56.46	—	—
	1,874	1,748	1,466	1,406	1,048	1,619	1,335
	478.94	448.76	375.83	362.17	272.58	406.89	337.85
	1,395	1,300	1,090	1,043	775.83	1,212	997.00
	84.64	78.88	66.15	63.35	47.12	73.84	63.07
Key metrics
	2,061	1,943	1,658	1,575	1,203	1,735	1,437
	42.95%	42.70%	40.30%	37.80%	33.30%	39.40%	41.50%
	29.06%	28.50%	26.50%	25.00%	21.50%	27.50%	28.80%
	—	16.10%	15.00%	—	—	—	—
	15.86%	10.60%	-1.20%	15.20%	-17.80%	27.10%	—
	22.76%	19.30%	4.40%	34.50%	-36.00%	21.60%	—
	—	917.30	938.56	—	—	—	—
	—	0.87	0.99	—	—	—	—
	—	0.00	0.00	—	—	—	—
	—	-3,178	-2,430	—	—	—	—
	—	184.4	178.3	—	—	—	—
Balance sheet
	—	11,607	10,422	—	—	—	—
	—	6,422	5,767	—	—	—	—
	—	3,178	2,433	—	—	—	—
	—	1,521	1,143	—	—	—	—
	—	1,265	1,254	—	—	—	—
	—	384.98	443.68	—	—	—	—
	—	1,684	1,736	—	—	—	—
	—	485.37	385.87	—	—	—	—
	—	633.02	523.76	—	—	—	—
	—	0.00	2.55	—	—	—	—
	—	0.00	1.44	—	—	—	—
	—	0.00	1.11	—	—	—	—
	—	10,810	9,755	—	—	—	—
Cash flow
	—	1,135	1,074	—	—	—	—
	—	-95.56	1,578	—	—	—	—
	—	-316.18	-339.54	—	—	—	—
	—	217.93	135.11	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +7.97%
Sales CAGR 5Y: +5.62%
Profit CAGR 3Y: +18.76%
Profit CAGR 5Y: +5.44%
Sales YoY (TTM): +15.86%
Profit YoY (TTM): +22.76%

Consolidated

Sales CAGR 3Y: +21.06%
Sales CAGR 5Y: +13.18%
Profit CAGR 3Y: +9.57%
Profit CAGR 5Y: +0.60%
Sales YoY (TTM): +17.57%
Profit YoY (TTM): +46.55%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 45.75%

Quarter	September 2026	June 2026
Promoter %	45.75%	51.77%

Holder	Type	Holding	Previous	Change
Fosun Pharma Industrial Pte. Ltd	Promoter	45.75%	51.77%	-6.02%
Hdfc Mutual Fund - Hdfc Mid-Cap Fund	Public	5.60%	6.11%	-0.51%
Nippon Life India Trustee Ltd- A/C Nippon India Growth Mid Cap Fund	Public	4.87%	4.93%	-0.06%
Sbi Large & Midcap Fund	Public	3.20%	3.32%	-0.12%
Mirae Asset Large & Midcap Fund	Public	2.92%	5.69%	-2.77%
Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund A/C Axis Small Cap Fund	Public	2.51%	—	—
Kotak Midcap Fund	Public	2.42%	—	—
Dsp Small Cap Fund	Public	1.57%	1.62%	-0.05%
Hdfc Life Insurance Company Limited	Public	1.51%	—	—
Icici Prudential India Opportunities Fund	Public	1.41%	1.79%	-0.38%
Government Pension Fund Global	Public	1.32%	1.34%	-0.02%
Uti-Flexi Cap Fund	Public	1.23%	1.22%	+0.01%
Canara Robeco Mutual Fund A/C Canara Robeco Small Cap Fund	Public	1.06%	—	—
Ample Up Limited	Promoter Group	0.00%	0.00%	0.00%
Regal Gesture Limited	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%

Filings & corporate actions

Recent announcements

Gland Pharma receives approval for Methylprednisolone Acetate Injectable Suspension USP, Single Dose and Multiple Dose Vials3 Nov 2026 · Company Update / Press Release / Media Release
Appointment of Mr. Ajay Sahni as the Chief Executive Officer of Gland Pharma International Pte. Ltd (Wholly owned subsidiary of Gland Pharma Limited)30 Oct 2026 · Company Update / Change in Management
Conclusion of USFDA Unannounced Inspection at Company''s Formulation Facility at Dundigal, Hyderabad23 Oct 2026 · Company Update / General
Q2FY27 Earnings Call Intimation21 Oct 2026 · Company Update / Analyst / Investor Meet
Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2026 ,inter alia, to consider and approve Unaudited Financial Results for ....21 Oct 2026 · Board Meeting / Board Meeting
Certificate under Reg 74(5) of the SEBI (DP) Regulations, 201812 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Newspaper Publication regarding the dipatch of Notice of Postal Ballot7 Oct 2026 · Company Update / Newspaper Publication
Postal Ballot Notice6 Oct 2026 · AGM/EGM / Postal Ballot
Resignation of Mr. Wenjie Zhang as a Non-Executive & Non-Independent Director and Appointment of Mr. Xingli Wang as an Additional Director (Non-Executive and Non-Independent Director)1 Oct 2026 · Company Update / Change in Directorate
Investment by Gland Pharma Limited in Gland Pharma USA Inc. and Investment by Gland Pharma USA Inc. into Novelstar Pharma Inc.1 Oct 2026 · Company Update / Acquisition
Outcome of Board Meeting held on October 01, 20261 Oct 2026 · Others / Outcome without intimation
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Fosun Pharma Industrial Pte Ltd1 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Closure of Trading Window30 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mirae Asset Mutual Fund30 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Copy of Newspaper Publication29 Sep 2026 · Company Update / Newspaper Publication
Acquisition of Gland Pharma USA Inc., a wholly-owned Step down subsidiary from Gland Pharma International Pte. Ltd, a wholly-owned subsidiary of the Company13 Sep 2026 · Company Update / Acquisition
Outcome of Board Meeting13 Sep 2026 · Others / Outcome without intimation
Allotment of 44,193 Equity Shares on exercise of ESOPs13 Sep 2026 · Company Update / Allotment of ESOP / ESPS
Grant of Stock Options under Gland Pharma Employee Stock Option Scheme, 202513 Sep 2026 · Company Update / General
Board Comments on fines levied by Exchanges13 Sep 2026 · Company Update / General
Schedule of Investor Meetings10 Sep 2026 · Company Update / Analyst / Investor Meet
Investor Meet Intimation8 Sep 2026 · Company Update / Analyst / Investor Meet
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Fosun Pharma Industrial Pte Ltd8 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Schedule of Investor Meet Intimation4 Sep 2026 · Company Update / Analyst / Investor Meet
Conclusion of USFDA Inspection at Company''s Facilities situated at Visakhapatnam1 Sep 2026 · Company Update / General
Schedule of Investor Meets31 Aug 2026 · Company Update / Analyst / Investor Meet
48th AGM Voting Results along with Scrutinizers Report26 Aug 2026 · AGM/EGM / AGM
48th AGM Outcome25 Aug 2026 · AGM/EGM / AGM
Schedule of Investor Meet23 Aug 2026 · Company Update / Analyst / Investor Meet
Q1FY27 Earnings Call Transcript17 Aug 2026 · Company Update / Earnings Call Transcript
Appointment of Chief Executive Officer of the Company14 Aug 2026 · Company Update / Change in Management
Newspaper Publication on Q1FY27 Financial Results11 Aug 2026 · Company Update / Newspaper Publication
Q1FY27 Earnings Call Audio recording10 Aug 2026 · Company Update / Analyst / Investor Meet
Schedule of Investor Meets10 Aug 2026 · Company Update / Analyst / Investor Meet
Investor Presentation on Q1FY27 Financial Results10 Aug 2026 · Company Update / Investor Presentation
Press release on Q1FY27 Financial Results10 Aug 2026 · Company Update / Press Release / Media Release
Outcome of Board Meeting10 Aug 2026 · Board Meeting / Outcome of Board Meeting
Unaudited Financial results for the quarter ended June 30, 202610 Aug 2026 · Result / Financial Results
Gland Pharma announces strategic CDMO partnership with a Global Pharmaceutical Company9 Aug 2026 · Company Update / Press Release / Media Release
Gland Pharma announces strategic collaboration with Neuland Laboratories for sterile API Manufacturing5 Aug 2026 · Company Update / Press Release / Media Release

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 20.0000	11 Aug 2026	11 Aug 2026	—
Final Dividend - Rs. - 18.0000	14 Aug 2025	14 Aug 2025	—
Final Dividend - Rs. - 20.0000	16 Aug 2024	16 Aug 2024	—

Board meetings

6 Nov 2026 Board Meeting - Financial Results
10 Aug 2026 Board Meeting - Financial Results